2CUREX AB The shareholders of
Notification of participation etc.
Shareholders who wish to attend the extraordinary general meeting must:
- be recorded as shareholders in the share register maintained by
Euroclear Sweden AB on Thursday 4st ofJuly 2024 , and; - no later than Monday 8st of
July 2024 have given written notice of their participation by mail to2cureX AB , c/oTalenom Consulting AB , Lilla Strandgatan, 261 22 Landskrona. Notice can also be done by email to ir@2curex.com. The notification should state name, personal identification number or registration number, address, daytime phone number and when applicable information regarding any representative, proxy and or at most two assistants. If applicable, the notification must include authorization documents such as a certificate of registration or equivalent documents.
Nominee-registered shares
A shareholder who has its shares registered with a nominee must, to be entitled to participate in the extraordinary general meeting, have the shares registered in its own name through the nominee, so that the shareholder is registered in the share register kept by
Proxy
Shareholders represented by proxy shall issue a written and dated power of attorney signed by the shareholder. A power of attorney issued by a legal entity shall have a registration certificate attached, or if such certificate does not exist, equivalent documents. The original power of attorney and any registration certificate should, in advance of the extraordinary general meeting, be sent to the company at the address above.
Proposed agenda
- Appointment of a Chairman of the extraordinary general meeting
- Preparation and approval of the voting register
- Approval of the agenda
- Appointment of one (1) or two (2) persons to verify the minutes of the meeting
- Determination of whether the extraordinary general meeting was duly convened
- Sale of 2cureX A/S.
- Closure of the extraordinary general meeting
Sale of 2cureX A/S (item 6)
Major shareholders proposes that the extraordinary general meeting of 2cureX approves the sale of 100 percent of the shares in the Danish subsidiary 2cureX AS, reg.no 29418888, (the "Subsidiary") to
2cureX and the Subsidiary intend to establish a close collaboration and act in synergy to make drug sensitivity testing part of daily practise at oncology hospitals.
The transaction was described in a public press release on
The Board of Directors intends to propose to distribute proceeds from the sale of the Subsidiary proportionally to all
In relation to the proposed sale of the Subsidiary, the Board of Directors has asked EY to provide an independent fairness opinion. EY will document their work in a brief written confidential report to the Board of Directors in English, summarizing the relevant background, methodologies applied, assumptions and findings including a conclusion as to whether EY views the offer as fair from a shareholder perspective. The confidential valuation report is meant for internal use by the Board of Directors of
Other
The notice, the EY statement and proxy forms will be made available at the premises of the company, 2cureX, Fruebjergvej 3, 2100
Shareholders are informed of their right under Chapter 7, Section 32 of the Swedish Companies Act to request information from the Board of directors and the CEO.
___________
Malmö in
The Board of Directors
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in
© Modular Finance, source
